ID: ALA4756418

Max Phase: Preclinical

Molecular Formula: C30H32N2O6S

Molecular Weight: 548.66

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC(C)(C)OC(=O)N1CC[C@]2(C(=O)Nc3ccccc32)[C@H]1c1cccc(-c2ccc(CO)c(S(C)(=O)=O)c2)c1

Standard InChI:  InChI=1S/C30H32N2O6S/c1-29(2,3)38-28(35)32-15-14-30(23-10-5-6-11-24(23)31-27(30)34)26(32)21-9-7-8-19(16-21)20-12-13-22(18-33)25(17-20)39(4,36)37/h5-13,16-17,26,33H,14-15,18H2,1-4H3,(H,31,34)/t26-,30-/m1/s1

Standard InChI Key:  WCOXMLFEWOILDZ-PDDLMNHVSA-N

Associated Targets(Human)

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha 132 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta 97 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

LXR-beta 3841 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

U-87 MG 3946 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 548.66Molecular Weight (Monoisotopic): 548.1981AlogP: 4.82#Rotatable Bonds: 4
Polar Surface Area: 113.01Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.13CX Basic pKa: CX LogP: 3.53CX LogD: 3.53
Aromatic Rings: 3Heavy Atoms: 39QED Weighted: 0.48Np Likeness Score: -0.06

References

1. Chen H,Chen Z,Zhang Z,Li Y,Zhang S,Jiang F,Wei J,Ding P,Zhou H,Gu Q,Xu J.  (2020)  Discovery of new LXRβ agonists as glioblastoma inhibitors.,  194  [PMID:32248003] [10.1016/j.ejmech.2020.112240]

Source